Caring to make a difference
Bioshares Newsletter “Biotech IPO Window: “Open” January 2011.
The Australian Financial Review “Biotechs gear up to rival resources” January 2011.
Genscreen announces that the in-house RESET project has completed initial testing and shall be renamed “Hervian”
Ian Dixon, CEO of Genscreen Pty Ltd, announces that Genscreen is presently having TR400 drugs sythesised by a contractor. It is anticipated that screening results will be ready for review by March 2010
Genscreen announces the interim results of its preclinical development projects